Monday, December 10, 2012
B.V.'s T-Guard, a mAb-toxin fusion protein that blocks activation of T
cells associated with graft-versus-host disease, is being developed to provide faster
symptom relief and better safety than high-dose corticosteroids now used in
GvHD patients who have failed first-line treatment.
occurs when T cells in allogeneic stem cell transplants begin attacking the
host's tissues. These T cells activate additional immune system cells such as
monocytes and natural killer (NK) T cells, resulting in damage to the
epithelial cells of the skin, liver and gut.